teva pharmaceutical industries ltd nasdaq sector heathcare industry biotechnology and drugs function of the company incorporated on february 13 1944 is a global producing in all major treatment categories has utilized its production research capabilities to establish business focused growing demand for generic opportunities proprietary branded products specific niche s active ingredients provides both significant revenues profits from sales third party manufacturers strategic benefits own through cost effective timely delivery raw materials snapshot total ttm 2 52 billion assets 5 43 rank by market cap 6 capitalization 14 568 fundamental analysis 1 valuation ratio comparison p e 26 83 40 21 30 49 24 79 eco eind undervalued compared & but slightly overvalued peg1 0 93 91 66 38 pegco indices this due high growth rate around 28
